Pfizer pays 5.85% to wait out a patent cliff. Is $29 already paying for 2028?

A $1.5 billion guidance raise that bought the stock a 2.2% drop

Pfizer ($PFE) reported revenue of $16.58 billion for the quarter to September 2026, flat against $16.65 billion in the same quarter of 2025, and adjusted earnings per share of $0.87 - also flat, but 17.6% above the $0.74 analysts expected. Without the two COVID products sales grew 7%; launched and acquired products grew 32% to $3.8 billion. Eliquis rose 25% to $2.52 billion despite a Medicare negotiated price in force since 1 January 2026, while Paxlovid fell 63% to $449 million and Comirnaty 29% to $808 million.

Management lifted 2026 guidance a second time, to $62-64 billion of revenue and $2.95-3.05 of adjusted EPS, from $60.5-62.5 billion and $2.80-3.00, and the EPS range absorbs a $0.10 hit from a $650 million Innovent licensing charge. The stock fell 2.2% on 4 November, hit a 52-week high of $31.44 on 5 November and closed at $29.39 on 6 November, the $0.43 ex-dividend day. Five beats in a row, two raises, and the price has gone nowhere.

41x earnings on paper, under 10x on the forecast

The headline P/E of 41.5x is an accounting artefact. Net income for the nine months to 27 September 2026 fell 40% to $5.68 billion because Pfizer wrote off $3.8 billion on the cancer drug sigvotatug vedotin and $525 million on Oxbryta in the first half of 2026, plus $1.05 billion of legal charges. None of it is cash leaving the building in 2026.

On the $3.00 midpoint of the adjusted EPS guidance the stock trades at 9.8x - a multiple the market gives a business it expects to shrink - and at 14.2x free cash flow. The peer leg of the model sees the GAAP version: an EV/EBITDA of 18.1x against an industry median of 13.5x and a P/E of 41.5x against 21.3x make Pfizer look expensive next to other drugmakers, which weighs on 30% of the fair value.

$7.3 billion of dividends, $62.9 billion of debt, a $20.7 billion patent bill

The 10-Q filing shows operating cash flow of $8.83 billion for the nine months to 27 September 2026, up from $6.36 billion in the same period of 2025, and capital spending of $1.54 billion, so free cash flow - cash from operations minus investment in plant - was $7.28 billion against $7.35 billion of dividends paid. The third quarter alone generated about $4.8 billion, twice the quarterly dividend bill. Debt principal is $62.9 billion against $14.3 billion of cash and short-term investments, leverage is 2.6x EBITDA, and no shares have been bought back in 2026 despite a $3.3 billion authorisation.

The bill is the calendar. Eliquis ($7.96 billion of revenue in 2025), the Vyndaqel family ($6.38 billion), Ibrance ($4.12 billion) and Xtandi ($2.19 billion) together earned $20.66 billion in 2025, 33% of the $62.58 billion total. The 2025 annual report puts the US patent expiry of Ibrance and Xtandi in 2027, with Medicare negotiated prices for both from 2027, and permits Eliquis generics from 1 April 2028. Pfizer expects a $1.1 billion revenue hit from expiries in 2026 and a sharp acceleration after that; consensus has 2027 revenue at about $59.9 billion, down 3.8%, and adjusted EPS at $2.89. Management's answer: $7.2 billion of cost savings by the end of 2026, $2.5 billion more over 2027-2029, and high-single-digit revenue growth from 2028 to 2033.

Fair value $33.03: why the model sits $2.53 above Wall Street's median

The FPI fair value is $33.03, 12.4% above the $29.39 price. The half of the model that is a discounted cash flow rewards what Pfizer has today: a free cash flow yield of 7.04% (industry median 4.37%), a free cash flow margin of 18.5% and a 5.85% dividend yield against a 2.23% median. A business that turns $18.50 of every $100 of sales into spare cash keeps its value through a few shrinking years, because a DCF counts the cash of 2027 and 2028 as much as 2031. The peer leg pulls the other way; the consensus leg anchors on a mean target of $31.13.

Street vs model: of 40 analysts, 16 say buy, 23 hold, 1 sell. Targets run from $26 to $40, with a median of $30.50 - just 3.8% above the price - and a mean of $31.13. The model sits 8.3% above the median and 6.1% above the mean. The newest notes are closer: Argus moved to $40 on 4 November 2026, FBN Securities to $34 on 6 November and Scotiabank to $33 on 6 October; Cantor Fitzgerald held $28 on 8 October and HSBC $30 on 10 September, after downgrading to Hold on 6 July 2026, the day of the $23.62 52-week low. The five targets of the quarter to 6 November average $33.00, matching the model to the dollar; the gap is between fresh notes and stale ones.

The most likely reason the median lags: the Street models a 3.8% revenue decline in 2027 and will not pay for growth after 2028 before it sees 2027 guidance. Insiders did not wait. CEO Albert Bourla bought 38,000 shares at $26.34 on 12 August 2026, about $1.0 million, and two directors each bought roughly $1 million on 5 August.

Three dates before 2 February 2027 and two price levels that settle it

What would move the stock toward $33: 2027 guidance, due in mid-December 2026, at or above $60 billion of revenue and $2.90 of adjusted EPS, which would mean a shallower cliff than consensus assumes; and a December declaration above the $0.43 paid every quarter since early 2025. What would push it toward the $26.91 200-day average: a 2027 revenue guide below $59 billion, leverage above the 2.7x target as the Metsera obesity trials absorb cash, or fourth-quarter results on 2 February 2027 (consensus EPS $0.69 on $17.14 billion of revenue) breaking the five-quarter beat streak.

Signals to watch:

• 2027 revenue guidance against $59.9 billion consensus, mid-December 2026.
• The December 2026 dividend declaration: $0.43 or higher.
• Price against the $31.44 high and the $26.91 200-day average.

At $29.39 a holder collects 5.85% a year while the market decides whether 2028 is a cliff or a step; the model prices the cash on the way there at $3.64 a share more.